Michael E. Faerm
CIK 1647141 · Chief Financial Officer · last filed 2026-03-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.35M
Companies
3
Total Filings
11
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Viracta Therapeutics, Inc. (VIRX) Delisted | Chief Financial Officer | — | $0.01 | — | $0 | 1 | 2024-05-16 |
| INVA | Sr VP & Chief Business Officer | 279,422 | $22.74 | $6.35M | $0 | 8 | 2017-11-22 |
| Innoviva, Inc. (THRX) Delisted | Sr VP & Chief Business Officer | 105,288 | $4.06 | $427.5K | $0 | 1 | 2015-07-27 |
Recent Filings · Page 2 of 2
11 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-07-27 | Innoviva, Inc. (THRX) Delisted | Grant (A) | +105,288 | $0 | EDGAR |
Showing 11–11 of 11
Prev
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.